Executive Summary: On May 15, 2026, China's National Medical Products Administration (NMPA) officially released the Implementation Measures for Drug Test Data Protection, which formally establishes a regulatory data exclusivity (RDE) framework in Mainland China. Under this framework, eligible undisclosed CMC, nonclinical and clinical-related data may receive up to six years of protection. This article provides a summary and preliminary interpretation of the drug test data protection requirements applicable to CHEMICAL DRUGS, including innovative drugs, modified new drugs, and generic drugs.
Legal Foundation of China's Data Exclusivity Regime
The new regulatory framework is anchored in two primary legislative updates implemented simultaneously on May 15, 2026:
Article 22 of the Fourth Revised Implementation Regulations of the PRC Drug Administration Law (promulgated January 16, 2026).
NMPA Announcement No. 47 of 2026: Measures for the Implementation of Drug Test Data Protection Policy (issued and effective May 15, 2026).
These regulations reflect a clear trend toward alignment with the regulatory data exclusivity frameworks adopted by the US FDA and EMA, particularly in terms of innovation incentives, reliance restrictions, and structured exclusivity periods. However, the Chinese framework still retains certain distinctive features in both regulatory design and implementation approach.
Exclusivity Periods by Drug Classification
Under the new NMPA rules, drugs can be granted a regulatory data exclusivity period of up to six years, depending on the registration classification. The exclusivity period is calculated from the official marketing authorization (MA) approval date in Mainland China.
Table 1. Chemical Drug Registration Categories and Data Protection Periods
| Registration Categories | Description | Data Protection Period | Notes |
|---|---|---|---|
| Class 1 | Innovative drugs not yet marketed anywhere globally | 6 years | / |
| Class 2 | Modified new drugs not yet marketed globally | 4 years | For originator drugs already marketed overseas but not in China, where the first application for a new indication (not approved anywhere globally) is submitted in China and meets the criteria under Article 7, Paragraph 1 of the Measures, the data protection period is 6 years. |
| Class 3 | Drugs developed by Chinese applicants referencing originator drugs approved overseas but not yet approved in China | 3 years | Applies only to the first approved product of the same drug product in China. |
| Class 4 | Drugs developed by Chinese applicants referencing originator drugs already marketed in China | - | No data protection granted. |
| Class 5 | Overseas-marketed drugs applying for marketing approval in China | ||
| 5.1 | Overseas-marketed originator drugs applying for marketing approval in China | 6 years | If meeting the criteria under Article 7, Paragraph 2 of the Measures, the data protection period is 4 years. |
| Overseas-marketed modified drugs applying for marketing approval in China | 4 years | ||
| 5.2 | Overseas-marketed generic drugs (not yet approved in China) applying for marketing approval in China | 3 years | Applies only to the first approved product of the same drug product in China; generic drugs referencing originator drugs already marketed overseas but not yet in China. |
Scope of Protected Test Data
The NMPA's data protection covers undisclosed, independently generated test data submitted in the marketing authorization application to prove safety, efficacy, and quality controllability. The scope encompasses three primary categories:
CMC (Chemistry, Manufacturing, and Control) Data
Includes API and drug product research, manufacturing processes, specification and analytical method development, stability studies, and packaging material compatibility research.
Non-Clinical Study Data
Including but not limited to pharmacodynamic, pharmacokinetic, toxicological, and safety pharmacological research.
Clinical Trial Data
Includes early-stage clinical (Phase I/II) data and pivotal clinical (Phase III) data.
Key Exclusions from Protection
However, the following data types are explicitly excluded from regulatory data exclusivity:
Bioavailability (BA) and Bioequivalence (BE) study data.
Vaccine immunogenicity data.
Post-marketing clinical trial data generated under conditional approvals.
Restrictions and Timelines for Follow-on Applicants
During the active exclusivity period, third-party applicants are prohibited from "relying" on the protected data to secure marketing approvals or supplemental approvals without the explicit consent of the original Marketing Authorization Holder (MAH).
Defining "Reliance"
"Reliance" refers to the regulatory pathway where follow-on applicants — such as developers of generics or improved modified new drugs — reference or cite the originator's undisclosed safety and efficacy data in their dossiers, rather than independently conducting duplicative studies (e.g., preclinical or clinical trials).
The "One-Year Window" Rule for Follow-on Filings
Follow-on applicants are permitted to submit marketing authorization applications and supplementary applications relying on the protected data within one year prior to the expiration of the exclusivity period. The Center for Drug Evaluation (CDE) will accept and complete the technical review of such applications; however, the review timeline will be suspended upon completion of the technical review, and final marketing approval will only be issued after the data exclusivity period has fully expired.
Additionally, for generic drugs referencing an originator drug approved overseas but not yet marketed in China, if the same generic product had already obtained marketing approval in China prior to the issuance of the Measures, subsequent applicants are exempt from repeating clinical studies for safety and efficacy. Such exemption applies starting two years after the date of the first approval of the generic product in China.
Registration applications submitted by other applicants relying on protected data may be accepted or approved from the date on which NMPA issues an announcement formally terminating the data protection period.
Public Disclosure of Data Protection Information
For drugs granted data exclusivity, the NMPA will indicate the relevant data protection information directly in the drug approval certificate. In addition, CDE will establish a dedicated section on its official website to publicly disclose data protection details.
Transitional Policies and Critical Deadlines
The NMPA has established strict transitional rules that require immediate action from pharmaceutical companies with pending or recently approved drugs in China.
Class 1 Innovative Chemical Drugs Approved Between May 15, 2020, and May 14, 2026
CDE released two general technical Q&A items on May 15, 2026, to clarify the application process for this cohort. The applicable process is as follows:
Interim Freeze Period
From May 15, 2026, until CDE officially publishes the approved data protection information on its website, no follow-on registration applications relying on the protected test data will be accepted or approved.
Previously Accepted Follow-on Applications
For generic or other applications relying on protected data that were already accepted before May 15, 2026, CDE will continue the review process and suspend the review timeline upon completion of the technical review. The application will then be submitted to the NMPA 14 working days prior to the expiration of the data protection period. During the suspension period, if the applicant independently supplements additional studies capable of replacing the protected data, CDE may resume the review and proceed to approval if all applicable requirements are met.
Appendix: Frequently Asked Questions
A: Class 1 innovative chemical drugs approved between May 15, 2020, and May 14, 2026, must submit a formal data protection application along with all supporting documents to CDE by June 5, 2026. CDE will review the eligibility and submit its conclusions to the NMPA by June 26, 2026. Drugs that meet the eligibility requirements will be publicly announced on the CDE official website upon NMPA approval.
Prior to the public disclosure of data protection information on the CDE website, drug registration applications relying on the protected data of innovative chemical drugs approved between May 15, 2021 and May 14, 2026, will not be accepted; and drug registration applications relying on the protected data of innovative chemical drugs approved between May 15, 2020 and May 14, 2026, will not be approved.
A: For drug registration applications that rely on protected test data of the innovative chemical drugs mentioned in Q1 and that have already been accepted before May 15, 2026, CDE will continue the review process and suspend the review timeline upon completion of the technical review. The application will be submitted to the NMPA for final approval 14 working days prior to the expiration of the data exclusivity period.
During the suspension period, if the applicant independently generates supporting research data without relying on any third party's protected data, such data may be submitted to CDE. If the submitted data meet all applicable regulatory requirements, the review and approval process will resume.
Not sure how to navigate China's new data exclusivity regime? Our regulatory experts are ready to help.
Email: customer@reach24h.com
